Quantum precision reached in modeling molten salt behavior
A new tool that simulates the energy profile of every building in America will give homeowners, utilities and companies a quick way to determine energy use and cost-effective retrofits that can reduce energy and carbon emissions.
Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Scientists at Oak Ridge National Laboratory have developed a solvent that results in a more environmentally friendly process to recover valuable materials from used lithium-ion batteries, supports a stable domestic supply chain for new batteries
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
Scientists at Oak Ridge National Laboratory have devised a method to identify the unique chemical makeup of every lithium-ion battery around the world, information that could accelerate recycling, recover critical materials and resolve a growing waste stream.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.